ResearcherSalk Institute for Biological StudiesNo recent work listed
Gaoyang Liang
Matched on ORCID iD 0000-0002-2157-974X; OpenAlex author ID A5015068404; NIH RePORTER profile ID 11548223. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 29
2019: 1 paper, 1 grant · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 4
- Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
- Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Co-author DOI 10.1016/j.medj.2021.12.008↗
- Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
- Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
Grants 1
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ronald M. Evans · 4 shared papers, 2019–2023 · strength 0.40
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. DOI 10.1016/j.medj.2021.12.008↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Daniel D. Von Hoff · 4 shared papers, 2019–2023 · strength 0.40
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. DOI 10.1016/j.medj.2021.12.008↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Yu Shi · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Corina E. Antal · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Tony R. Hunter · 3 shared papers, 2019–2023 · strength 0.28
- Paper Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. DOI 10.1038/s41467-023-42178-6↗
- Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
- Paper Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-019-1130-6↗
- Serina Ng · 2 shared papers, 2022–2023 · strength 0.25
- Haiyong Han · 2 shared papers, 2022–2023 · strength 0.25
- Timothy R. Donahue · 2 shared papers, 2019–2021 · strength 0.14
- Kathleen E. DelGiorno · 2 shared papers, 2019–2021 · strength 0.14
- Nikki K. Lytle · 2 shared papers, 2019–2021 · strength 0.14
- Geoffrey Myles Wahl · 2 shared papers, 2019–2021 · strength 0.14
- Maya Ridinger-Saison · 2 shared papers, 2019–2021 · strength 0.14
- Ruilian Xu · 2 shared papers, 2019–2021 · strength 0.14
- Peiwu Huang · 2 shared papers, 2019–2021 · strength 0.14
- Carlos Roberto Becerra · 2 shared papers, 2019–2021 · strength 0.14
- Eric Andrew Collisson · 2 shared papers, 2019–2021 · strength 0.14
- Michael Anthony Hollingsworth · 2 shared papers, 2019–2021 · strength 0.14
- Paul M. Grandgenett · 2 shared papers, 2019–2021 · strength 0.14
- Andrew M. Lowy · 2 shared papers, 2019–2021 · strength 0.14
- Erkut Hasan Borazanci · 2 shared papers, 2019–2021 · strength 0.14
- Tannishtha Reya · 2 shared papers, 2019–2021 · strength 0.14
- Ruijun Tian · 2 shared papers, 2019–2021 · strength 0.14
- Dannielle D. Engle · 1 shared paper, 2023 · strength 0.13
- Hervé Tiriac · 1 shared paper, 2023 · strength 0.13
- Wenyun Lu · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.